Skip to main content
Top
Published in: Tumor Biology 7/2016

Open Access 01-07-2016 | Original Article

Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?

Authors: Anita Chudecka-Głaz, Aneta Cymbaluk-Płoska, Jolanta Jastrzębska, Janusz Menkiszak

Published in: Tumor Biology | Issue 7/2016

Login to get access

Abstract

After several years of research, HE4 was found to be characterized by slightly worse sensitivity but significantly higher specificity as compared with CA125. Further studies led to the diagnostic potential of both markers (CA125 and HE4) being combined in a single risk of malignancy algorithm (ROMA) algorithm. The objective of this study was to assess the diagnostic capabilities of the ROMA algorithm using age ranges instead of dichotomization of patients according to the pre- and postmenopausal status. A total of 413 female patients were included in the study, including 162 premenopausal and 251 postmenopausal women. Calculation of the final ROMA values was achieved by means of stepwise reduction of coefficients in the proposed formula of: %ROMA = exp(PI)/[1-exp(PI)]*100) and PI = A + W(HE4)*ln(HE4) + W(CA125)*ln (CA125) and the arrangement of values with consideration to the age group, HE4 level, differentiation of modification, and directional coefficients as well as determination of individual deviations affecting the widening of the median. The cutoff value of modified algorithm ROMA P for the entire study population was calculated from receiver operating characteristic (ROC) curve and DeLong method at the levels of 23.5 %. Marked higher sensitivity and negative predictive value (NPV) values are observed for the standard ROMA algorithm while higher specificity and positive predictive value (PPV) values are observed for the modified algorithm ROMA P. The proposed age-related modification of algorithm calculation does not require the patients being dichotomized according to their pre- or postmenopausal status, and satisfactory diagnostic values may be obtained using a single cutoff point for the entire population.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S , Mathers C et al. Globocan 2012 v 1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globcan.iarc.fr. Accessed on 20 Jul 2014. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S , Mathers C et al. Globocan 2012 v 1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://​globcan.​iarc.​fr. Accessed on 20 Jul 2014.
2.
go back to reference Nelson HD, Fu R, Goddard K, Mitchell JP, Okinaka-Hu L, Pappas M, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. Preventive Services Task Force. Rockville: Recommendation Agency for Healthcare Research and Quality (US); 2013. Nelson HD, Fu R, Goddard K, Mitchell JP, Okinaka-Hu L, Pappas M, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. Preventive Services Task Force. Rockville: Recommendation Agency for Healthcare Research and Quality (US); 2013.
3.
go back to reference De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe, 1999–2007 by country and age: results of EUROCARE-5 a population based study. Lancet Oncol. 2014;15:23–34.CrossRefPubMed De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe, 1999–2007 by country and age: results of EUROCARE-5 a population based study. Lancet Oncol. 2014;15:23–34.CrossRefPubMed
4.
go back to reference Bast Jr RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:169–71.CrossRef Bast Jr RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:169–71.CrossRef
5.
go back to reference Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, Mcintosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695–700.PubMed Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, Mcintosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695–700.PubMed
6.
go back to reference Bandiera E, Romani C, Specchla C, Zanotti L, Galli C, Ruggieri G, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496–506.CrossRefPubMedPubMedCentral Bandiera E, Romani C, Specchla C, Zanotti L, Galli C, Ruggieri G, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496–506.CrossRefPubMedPubMedCentral
7.
go back to reference Ławicki S, Będkowska EG, Gacuta-Szumarska E, Szmitkowski M. The plasma concentration of VEGF, HE4 and CA 125 as new biomarkers panel in different stages and subtypes of epithelial ovarian tumors. J Ovarian Res. 2013;6:45.CrossRefPubMedPubMedCentral Ławicki S, Będkowska EG, Gacuta-Szumarska E, Szmitkowski M. The plasma concentration of VEGF, HE4 and CA 125 as new biomarkers panel in different stages and subtypes of epithelial ovarian tumors. J Ovarian Res. 2013;6:45.CrossRefPubMedPubMedCentral
8.
9.
go back to reference Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162–9.CrossRefPubMed Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162–9.CrossRefPubMed
10.
go back to reference Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, et al. The utility of human epididymal protein 4, cancer antigen 125, and risk form malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer. 2012;22:238–44.CrossRefPubMed Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, et al. The utility of human epididymal protein 4, cancer antigen 125, and risk form malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer. 2012;22:238–44.CrossRefPubMed
11.
go back to reference Langmár Z, Németh M, Vleskó G, Király M, Hornyák L, Bosze P. HE4- a novel promising serum marker in the diagnosis of ovarian carcinoma. Eur J Gynaecol Oncol. 2011;32:605–10.PubMed Langmár Z, Németh M, Vleskó G, Király M, Hornyák L, Bosze P. HE4- a novel promising serum marker in the diagnosis of ovarian carcinoma. Eur J Gynaecol Oncol. 2011;32:605–10.PubMed
12.
go back to reference Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402–8.CrossRefPubMed Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402–8.CrossRefPubMed
13.
go back to reference Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, et al. The ROMA (risk of ovarian malignancy algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011;49:521–5.CrossRefPubMed Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, et al. The ROMA (risk of ovarian malignancy algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011;49:521–5.CrossRefPubMed
14.
go back to reference Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203:e1–6.CrossRef Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203:e1–6.CrossRef
15.
go back to reference Ortiz-Munoz B, Aznar-Oroval E, Garcia AG, Peris AC, Ballestero PP, Yepes MS, et al. HE4, CA 125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumor Biol. 2014;35:7249–58.CrossRef Ortiz-Munoz B, Aznar-Oroval E, Garcia AG, Peris AC, Ballestero PP, Yepes MS, et al. HE4, CA 125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumor Biol. 2014;35:7249–58.CrossRef
16.
go back to reference Lenhardt M, Stieber P, Hertlein L, Kirschenhofer A, Furst S, Mayr D, et al. The diagnostic accuracy of two epididymis protein 4 (HE4) testing system in combination with CA 125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med. 2011;49:2081–8. Lenhardt M, Stieber P, Hertlein L, Kirschenhofer A, Furst S, Mayr D, et al. The diagnostic accuracy of two epididymis protein 4 (HE4) testing system in combination with CA 125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med. 2011;49:2081–8.
17.
go back to reference Plebani M. HE4 in gynecological cancers: report of a European investigators and experts. Clin Chem Lab Med. 2012;50:2127–36.PubMed Plebani M. HE4 in gynecological cancers: report of a European investigators and experts. Clin Chem Lab Med. 2012;50:2127–36.PubMed
18.
go back to reference Plebani M, Melichar B. ROMA or death: advances in epithelial ovarian cancer diagnosis. Clin Chem Lab Med. 2011;49:433–5. Plebani M, Melichar B. ROMA or death: advances in epithelial ovarian cancer diagnosis. Clin Chem Lab Med. 2011;49:433–5.
19.
go back to reference Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performance of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011;44:884–8.CrossRefPubMed Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performance of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011;44:884–8.CrossRefPubMed
20.
go back to reference Azzam AZ, Hashad DI, Kamel N. Evaluation of HE4 as an extra biomarker to CA 125 to improve detection of ovarian carcinoma: is it time for step forward. Arch Gynecol Obstet. 2013;288:167–72.CrossRefPubMed Azzam AZ, Hashad DI, Kamel N. Evaluation of HE4 as an extra biomarker to CA 125 to improve detection of ovarian carcinoma: is it time for step forward. Arch Gynecol Obstet. 2013;288:167–72.CrossRefPubMed
21.
go back to reference Andersen MR, Goff BA, Kimberly AL, Scholler N, Bergan L, Drescher C, et al. Use of a symptom index, CA 125 and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116:378–83.CrossRefPubMed Andersen MR, Goff BA, Kimberly AL, Scholler N, Bergan L, Drescher C, et al. Use of a symptom index, CA 125 and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116:378–83.CrossRefPubMed
22.
go back to reference Ferraro S, Bragna F, Lanzoni M, Boracchi P, Bignazoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen CA 125 for ovarian cancer diagnosis. J Clin Pathol. 2013;66:273–81.CrossRefPubMed Ferraro S, Bragna F, Lanzoni M, Boracchi P, Bignazoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen CA 125 for ovarian cancer diagnosis. J Clin Pathol. 2013;66:273–81.CrossRefPubMed
23.
go back to reference Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40–6.CrossRefPubMed Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40–6.CrossRefPubMed
24.
go back to reference Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118:280–8.CrossRefPubMedPubMedCentral Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118:280–8.CrossRefPubMedPubMedCentral
25.
go back to reference Kalapotharakos G, Asciutto C, Henic B, Casslen B, Borgfeldt C. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res. 2012;5:20.CrossRefPubMedPubMedCentral Kalapotharakos G, Asciutto C, Henic B, Casslen B, Borgfeldt C. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res. 2012;5:20.CrossRefPubMedPubMedCentral
26.
go back to reference Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Romani C, et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta. 2011;412:1447–53.CrossRefPubMed Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Romani C, et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta. 2011;412:1447–53.CrossRefPubMed
27.
go back to reference Molina R, Escudero JM, Auge JM, Filella X, Foj L, Torne A, et al. Her novel tumor marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumor Biol. 2011;32:1087–95.CrossRef Molina R, Escudero JM, Auge JM, Filella X, Foj L, Torne A, et al. Her novel tumor marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumor Biol. 2011;32:1087–95.CrossRef
28.
go back to reference Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol. 2013;128:233–8.CrossRefPubMed Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol. 2013;128:233–8.CrossRefPubMed
29.
go back to reference Karlsen MA, Sandhu N, Hodgall C, Christensen IJ, Nedergaad L, Lundvall L, et al. Evaluation of HE4, CA 125, risk of malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer patients with pelvic mass. Gynecol Oncol. 2012;127:379–83.CrossRefPubMed Karlsen MA, Sandhu N, Hodgall C, Christensen IJ, Nedergaad L, Lundvall L, et al. Evaluation of HE4, CA 125, risk of malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer patients with pelvic mass. Gynecol Oncol. 2012;127:379–83.CrossRefPubMed
30.
go back to reference Lowe K, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:2480–7.CrossRefPubMedPubMedCentral Lowe K, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:2480–7.CrossRefPubMedPubMedCentral
31.
go back to reference Moore RG, Miller MC, Eklund EE, Lu KH, Bast Jr RC, Lamber-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012;206:349E1–7.CrossRef Moore RG, Miller MC, Eklund EE, Lu KH, Bast Jr RC, Lamber-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012;206:349E1–7.CrossRef
32.
go back to reference Bolstad N, Oijordsbakken M, Neustad K, Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumor Biol. 2012;33:141–8.CrossRef Bolstad N, Oijordsbakken M, Neustad K, Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumor Biol. 2012;33:141–8.CrossRef
33.
go back to reference Park Y, Kim Y, Lee EY, Lee J, Kim H. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer. 2012;130:1136–44.CrossRefPubMed Park Y, Kim Y, Lee EY, Lee J, Kim H. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer. 2012;130:1136–44.CrossRefPubMed
34.
go back to reference Karlsen MA, Hogdall EV, Christensen IJ, Borgfeldt C, Kalapotharakos G, Zdrazilova-Dubska L, et al. A novel diagnostic index combining HE4, CA 125 and age may improve triage of women with suspected ovarian cancer—an international multicenter study in women with ovarian mass. Gynecol Oncol. 2015;138:640–6.CrossRefPubMed Karlsen MA, Hogdall EV, Christensen IJ, Borgfeldt C, Kalapotharakos G, Zdrazilova-Dubska L, et al. A novel diagnostic index combining HE4, CA 125 and age may improve triage of women with suspected ovarian cancer—an international multicenter study in women with ovarian mass. Gynecol Oncol. 2015;138:640–6.CrossRefPubMed
Metadata
Title
Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?
Authors
Anita Chudecka-Głaz
Aneta Cymbaluk-Płoska
Jolanta Jastrzębska
Janusz Menkiszak
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4733-z

Other articles of this Issue 7/2016

Tumor Biology 7/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine